PrognomiQ Raises $46M in Financing


PrognomiQ, a San Mateo, CA-based healthcare firm, raised $46M in funding.

The spherical, which brings complete funding to greater than $101m, was led by Bruker Company, with participation from Catalio Capital Administration, aMoon, Constancy Administration and Analysis Firm, T. Rowe Worth Associates, Invus, Maverick Ventures, Emerson Collective and Wing VC.

The corporate intends to make use of the funds to speed up the event of its platform and its pipeline of multi-omics merchandise for the early detection, remedy choice and monitoring of a number of cancers.

Based in September 2020 and led by CEO Philip Ma, PrognomiQ is a healthcare firm pursuing the event and commercialization of multi-omics human assessments for most cancers and different complicated illnesses. The corporate makes use of proteomics applied sciences, along with metabolomics and genomics applied sciences, to develop multi-omics merchandise to enhance human well being.

PrognomiQ generates wealthy phenotypic proteomic and metabolomics data and enhances this with large-scale genomics knowledge. The ensuing deep multi-omics knowledge gives excessive ranges of organic insights into most cancers illness mechanisms, in addition to into host response, and gives novel next-generation approaches to the detection and remedy choice and monitoring of a few of the most complicated illnesses.


Get latest news from African Startup ecosystem

Latest stories

You might also like...